DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Friday. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

DBVT stock opened at $4.87 on Friday. The company’s 50-day simple moving average is $4.37 and its 200 day simple moving average is $3.82. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $8.32. The company has a market capitalization of $100.17 million, a PE ratio of -1.08 and a beta of 0.71.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.